Abstract

Direct neuronal reprogramming, by which a neuron is formed via direct conversion from a somatic cell without going through a pluripotent intermediate stage, allows for the possibility of generating patient-derived neurons. A unique feature of these so-called induced neurons (iNs) is the potential to maintain aging and epigenetic signatures of the donor, which is critical given that many diseases of the CNS are age related. Here, we review the published literature on the work that has been undertaken using iNs to model human brain disorders. Furthermore, as disease-modeling studies using this direct neuronal reprogramming approach are becoming more widely adopted, it is important to assess the criteria that are used to characterize the iNs, especially in relation to the extent to which they are mature adult neurons. In particular: i) what constitutes an iN cell, ii) which stages of conversion offer the earliest/optimal time to assess features that are specific to neurons and/or a disorder and iii) whether generating subtype-specific iNs is critical to the disease-related features that iNs express. Finally, we discuss the range of potential biomedical applications that can be explored using patient-specific models of neurological disorders with iNs, and the challenges that will need to be overcome in order to realize these applications.

Highlights

  • Direct reprogramming of a terminally differentiated cell into another cell type was achieved for the first time in 1987 with the conversion of fibroblasts to myoblasts (Davis et al, 1987)

  • They found that there is an age-dependant loss of nucleocytoplasmic compartmentalization in donor fibroblasts which was kept in induced neuron (iN) but restored in induced pluripotent stem cells (iPSCs) derived from aged cells

  • They further demonstrated that RanBP17, a receptor that decreases with aging, was decreased in an age-dependent manner in iN cells—features that were both absent in iPSCs (Mertens et al, 2015a)

Read more

Summary

INTRODUCTION

Direct reprogramming of a terminally differentiated cell into another cell type was achieved for the first time in 1987 with the conversion of fibroblasts to myoblasts (Davis et al, 1987). Patient-Specific Induced Neurons for Disease Modeling iN cells, in contrast to induced pluripotent stem cells (iPSCs), are the result of direct reprogramming of one type of somatic cell into another without going through a pluripotent intermediate stage Because of this feature, it was hypothesized that iNs would retain some of the characteristics of the starting cell, especially related to epigenetic status and aging. In addition to a much shorter and easier reprogramming route, the most important difference known to date between neurons generated from iPSCs or directly from fibroblasts is the age of the cell It may be, though, that iPSC derived neurons will be best suited for modeling diseases associated with developmental processes whereas iNs will be most useful to study disorders associated with aging. HOMO, homozygous; ICC, immunocytochemistry; iDAN, induced dopaminergic neuron; IGF1, insulin-like growth factor 1; iMN, induced motor neuron; iN, induced neuron; iPSc, induced pluripotent stem cell; ISL1, insulin gene enhancer; LAMP1, lysosomal-associated membrane protein 1; LDH, lactate dehydrogenase; LHX3, LIM/homeobox; LM, LM-22A4; LMX1a/b, LIM homeobox transcription factor 1, alpha or beta; LRRK2, leucine-rich repeat kinase 2; MAP2, microtubuleassociated protein 2; MOI, multiplicity of infection; MYTL1, myelin transcription factor 1-like; NBIA, neurodegeneration with brain iron accumulation; NCAM, neural cell adhesion molecule; ND, not determined; NEUROD1 or 2, neurogenic differentiation 1 or 2; NF200, high molecular weight neurofilament subunit; NGN2, neurogenin-2; NLS, nuclear localization signal; NT3, neurotrophin; NURR1, nuclear receptor related 1; OLIG2, oligodendrocyte transcription factor 2; PD, Parkinson’s disease; PGK, phosphoglycerate kinase; PINK1, PTENinduced putative kinase 1; PKAN, pantothenate kinase-associated; PNS, peripheral nervous system; PSA-NCAM, polysialylated-neural cell adhesion molecule; PSD95, postsynaptic density protein 95; PSEN 1 or 2, presenilin 1 or 2; PTB, polypyrimidine tract-binding protein; R, repsox; RA, retinoic acid; RanBP17, RAN binding protein 17; REST, RE1-Silencing Transcription factor; RT-qPCR, realtime quantitative reverse transcription PCR; S, SP600125; SB, SB202190; SMA, spinal muscular atrophy; SNP, single-nucleotide polymorphism; SOX2, SRY (sex determining region Y)-box 2; SYN, synapsin; SYT1, synaptotagmin-1; TGFβ, transforming growth factor beta; TH, tyrosine hydroxylase; TUJ1, neuron-specific class III beta-tubulin; Ub, ubiquitin; UNO, unoprostone; V or VPA, valproic acid; VACHT, vesicular acetylcholine transporter; vGLUT, vesicular glutamate transporter; VIM, vimentin; WB, western blot; Y, Y-27632

20–40 ICC: MAP2
METHODS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call